Prothena (PRTA) Expected to Announce Earnings on Thursday

Prothena (NASDAQ:PRTA) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Prothena to post earnings of ($0.45) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Prothena Trading Up 1.2%

Shares of Prothena stock opened at $8.96 on Tuesday. The business’s fifty day simple moving average is $9.35 and its 200 day simple moving average is $9.37. Prothena has a 12 month low of $4.32 and a 12 month high of $16.67. The firm has a market capitalization of $482.32 million, a P/E ratio of -1.72, a price-to-earnings-growth ratio of 1.89 and a beta of -0.11.

Analyst Ratings Changes

A number of research firms have recently commented on PRTA. Chardan Capital upgraded Prothena to a “strong-buy” rating in a research note on Wednesday, November 19th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Prothena in a report on Monday, December 1st. Citigroup reaffirmed a “market outperform” rating on shares of Prothena in a research report on Monday, December 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Prothena in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $21.56.

Institutional Investors Weigh In On Prothena

A number of hedge funds and other institutional investors have recently bought and sold shares of PRTA. Squarepoint Ops LLC boosted its position in shares of Prothena by 71.6% in the fourth quarter. Squarepoint Ops LLC now owns 218,041 shares of the biotechnology company’s stock valued at $2,082,000 after acquiring an additional 91,008 shares during the period. Entropy Technologies LP bought a new stake in Prothena during the 4th quarter worth approximately $161,000. Barclays PLC lifted its stake in Prothena by 87.2% in the 4th quarter. Barclays PLC now owns 183,625 shares of the biotechnology company’s stock worth $1,754,000 after purchasing an additional 85,550 shares in the last quarter. Marshall Wace LLP bought a new position in Prothena in the 4th quarter valued at $523,000. Finally, Rubric Capital Management LP boosted its holdings in Prothena by 138.7% in the 4th quarter. Rubric Capital Management LP now owns 3,677,331 shares of the biotechnology company’s stock valued at $35,119,000 after purchasing an additional 2,136,958 shares during the period. Institutional investors own 97.08% of the company’s stock.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.